After a long hiatus, the Pharmacy Compounding Advisory Committee voted 33 times during a Feb. 23-24 meeting on recommendations for a list of drugs that should not be compounded as well as bulk substances that may be used in compounding medications.
Committee members recommended adding oxycodone hydrochloride to the do-not-compound list, but not without questions (see related story, [A#00150302007]). The review for both lists also caused FDA to update its...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?